Core Viewpoint - The company, Tuoxin Pharmaceutical, announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, following a rigorous scientific evaluation in accordance with the FDA's Generally Recognized as Safe (GRAS) criteria [1] Group 1 - The product Glyceryl Phosphoryl Choline has completed a strict scientific evaluation [1] - The Self-GRAS status indicates that the product is recognized as safe for its intended use [1] - This achievement may enhance the company's market position and product credibility in the pharmaceutical industry [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, under the FDA's Generally Recognized as Safe (GRAS) guidelines [1] Group 1: Product Information - Glyceryl Phosphoryl Choline is a naturally occurring choline compound in the human body and a key component of brain cell membranes [1] - It is recognized as a highly bioavailable source of choline with core benefits that have been validated through extensive research [1] Group 2: Core Benefits - The product is known to enhance cognitive function and support normal brain operation to maintain brain health [1] - It aids in improving athletic performance and post-exercise recovery [1] - It provides neuroprotective effects, ensuring the health of the nervous system [1]

Core Viewpoint - The company has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, through rigorous scientific evaluation in accordance with FDA's GRAS guidelines [1] Group 1: Product Information - Glyceryl Phosphoryl Choline is a naturally occurring choline compound in the human body and a key component of brain cell membranes [1] - It serves as a highly bioavailable source of choline, with core benefits including enhancement of cognitive function, support for normal brain operation to maintain brain health, improvement of athletic performance and post-exercise recovery, and neuroprotective effects for the health of the nervous system [1]

Core Viewpoint - Toxin Pharmaceutical's subsidiary, Jingquan Biotechnology, has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, from the FDA, which is a significant milestone for market entry in the U.S. and other regions recognizing FDA standards [1] Group 1 - Toxin Pharmaceutical's subsidiary, Jingquan Biotechnology, completed a rigorous scientific evaluation for Glyceryl Phosphoryl Choline [1] - The Self-GRAS certification is one of the highest levels of recognition established by the FDA for the safety of food additives and dietary ingredients [1] - The successful certification provides a critical "passport" for the product to enter the U.S. market and other international markets that recognize FDA standards [1]

Core Viewpoint - The company, Tuoxin Pharmaceutical, announced that its subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained Self-GRAS status for its product, Glycyrrhizin Choline, from the FDA, which is a significant milestone for entering the U.S. and other international markets that recognize FDA standards [1] Group 1: Regulatory Approval - The product Glycyrrhizin Choline has passed the FDA's Generally Recognized as Safe (GRAS) evaluation, securing a key "passport" for market entry [1] - This certification is expected to facilitate the expansion into high-end food, dietary supplements, and special medical food markets globally [1] Group 2: Market Impact - The approval is anticipated to optimize the company's product structure and enhance overall profitability [1] - However, future market promotion may face challenges from policy adjustments and intensified market competition, leading to uncertainty regarding the sales contribution to the company's overall operations [1]